Skip to main content

A randomized, double-blind, placebo-controlled study to assess the effect of repeated subcutaneous doses of SAR425899 on energy expenditure and safety in overweight to obese male and female subjects

A randomized, double-blind, placebo-controlled study to assess the effect of repeated subcutaneous doses of SAR425899 on energy expenditure and safety in overweight to obese male and female subjects

Principal Investigator

Sponsor

Sanofi Pasteur

The primary purpose of the study is to test if SAR425899 can affect energy expenditure.